ifosfamide

This report, representing the first documented case of LLMS from Central Asia, contributes to the limited global experience with this rare tumor. Our review identified four additional LLMS cases published between 2021 and 2024, totaling five recent reports including the present case. Collectively, these demonstrate persistent male predominance, glottic and supraglottic predilection, and survival outcomes consistent with previous observations. Complete surgical excision remains the cornerstone of therapy, while multidisciplinary-guided adjuvant treatment may benefit selected high-grade or high-risk patients. Continued accumulation and molecular characterization of cases are needed to refine prognostic assessment and optimize management strategies.

We report the case of a 26-year-old man with a primary mediastinal yolk sac tumor who progressed despite multimodal therapy, including etoposide, ifosfamide, and cisplatin chemotherapy, high-dose carboplatin and etoposide with autologous stem cell transplantation, gemcitabine and paclitaxel, surgical debulking, and radiation therapy. No further disease-directed therapies were available, and he ultimately died from progressive metastatic disease. This case highlights the aggressive biology of platinum-resistant primary mediastinal yolk sac tumors, illustrates primary resistance to programmed death-1 inhibition, and underscores the urgent need for more effective salvage strategies in this high-risk population.

Postoperatively, the patient received chemotherapy with epirubicin combined with ifosfamide. Follow-up showed no significant evidence of metastasis or recurrence. This report aims to provide clinical reference regarding the imaging findings and diagnosis of this rare disease, primary renal synovial sarcoma.

Interim PET/CT revealed in-field thoracic regression but widespread systemic progression; cisplatin-etoposide was added during the remaining RT course, followed by multisite palliative RT and consolidation cisplatin-etoposide-ifosfamide chemotherapy. This case suggests that staged, dose-escalated adaptive thoracic RT is feasible in selected patients with disseminated PPNC and compromised pulmonary function, providing durable in-field control and meaningful symptom palliation as part of a multimodal treatment approach. Molecular confirmation by NGS is essential for non-BRD4 fusions, and systemic therapy should be incorporated as early as safely feasible to address the high risk of distant dissemination.

This case highlights the diagnostic complexity of PSA in young adults presenting with unexplained anemia and splenic lesions. Bone marrow findings may be misleadingly reactive, underscoring the importance of histopathological confirmation of splenic tissue. Early recognition and prompt surgical intervention remain critical given the aggressive nature and poor prognosis of this malignancy.

This case highlights the diagnostic challenge of primary gastrointestinal ENKL in patients presenting with abdominal pain and hematochezia in the absence of computed tomography (CT) abnormalities. Persistent unexplained abdominal pain should prompt consideration of rare ulcerative small bowel diseases, including ENKL, particularly when perforation is a potential complication. Early multidisciplinary intervention is essential to improve the outcomes of this devastating condition.

The patient received Vincristine, Adriamycin, Cyclophosphamide Ifosfamide, Etoposide (VAC/IE) chemotherapy according to the European Ewing tumour Working Initiative of National Groups (EUROE.W.I.N.G.) protocol and achieved full neurological recovery. This case illustrates the diagnostic and therapeutic challenges posed by Ewing-like sarcomas in the absence of molecular confirmation. Function-preserving subtotal resection combined with multimodal chemotherapy may lead to excellent outcomes and may be preferable to radical resection when the latter carries a high neurological risk.

In selected non-metastatic H&N NUTc, durable control has been reported with timely systemic therapy plus curative-intent RT, often exceeding 50 Gy. This review summarizes dose concepts and case-based systemic regimens and provides a comparative table to support individualized treatment planning.

Case 1 was a 15-year-old female with 2 months history of a left breast mass that was painful, rapidly growing, and associated with ulceration; it was confirmed histologically to be MPT and was treated successfully with ifosfamide 390 mg, doxorubicin 48 mg, and dexamethasone 8 mg. MPTs are rare and are more likely to recur, and they tend to have rapid growth and metastasis. Timely and proper management of patients with MPT helps to prevent possibilities of metastasis and improve the prognosis of the patients.

This review summarizes the classification, subtype-specific characteristics, molecular mechanisms, treatment strategies, and prognosis of LPS, and further discusses how proteasome-associated mechanisms may create therapeutic vulnerabilities in selected subtypes. A better understanding of the molecular basis underlying tumor initiation, progression, and subtype transition may support the development of more precise and mechanism-based therapeutic strategies for LPS.

P2, N=406, Recruiting, Milton S. Hershey Medical Center | Not yet recruiting --> Recruiting

The patient initially received one cycle of adriamycin-ifosfamide-mesna (AIM), which was discontinued due to toxicity, followed by five cycles of vincristine-doxorubicin-cyclophosphamide (VDC), resulting in a near-complete metabolic response. Serial fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging confirmed a sustained complete metabolic remission beyond 18 months with minimal toxicity. This case highlights the marked chemosensitivity of BCOR-altered URCS to anthracycline-vinca-based chemotherapy and suggests a potential role for vascular endothelial growth factor (VEGF)-directed maintenance therapy in sustaining remission.